The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atacicept in Subjects With Lupus Nephritis in Combination With Mycophenolate Mofetil Therapy.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Prague, 128 50, Czech Republic
- Institute of Rheumatology
-
-
-
-
-
Kedah, Malaysia
- Hospital Sultanah Bahiyah
-
Kuala Lumpur, Malaysia
- University of Malaya Medical Centre
-
Kuala Lumpur, Malaysia
- Hospital University Kebangsaan Malaysia
-
Pulau Pinang, Malaysia
- Hospital Pulau Pinang
-
-
-
-
-
Singapore, Singapore
- Singapore General Hospital
-
Singapore, Singapore
- Changi General Hospital
-
-
-
-
-
Kaohsiung, Taiwan
- Kaohsiung Veterans General Hospital
-
-
-
-
Louisiana
-
New Orleans,, Louisiana, United States
- Tulane University Hospital and Clinic Department of Internal Medicine
-
Shreveport, Louisiana, United States, 71101
- Northwest Louisiana Nephrology Research
-
-
Michigan
-
Detroit, Michigan, United States
- Wayne State University Lupus Database Departments of Internal Medicine and Obstetrics & Gynecology Division of Rheumatology Wayne State University School of Medicine
-
-
New York
-
Manhasset, New York, United States, 11030
- The Feinstein Institute for Medical Research
-
New York, New York, United States, 10003
- Seligman Center for Advanced Therapeutics
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27109
- Wake Forest University Health Sciences
-
-
Ohio
-
Beachwood, Ohio, United States, 44122
- Rheumatology Clinical Research Unit, Division of Rheumatology University Hospitals Case Medical Center
-
Cincinnati, Ohio, United States, 45267
- University of Cincinnati College of Medicine
-
Columbus, Ohio, United States, 43210
- The Ohio State University Medical Center
-
Middleburg Heights, Ohio, United States, 44130
- Southwest Rheumatology and Research Group, LLC
-
-
South Carolina
-
Columbia, South Carolina, United States, 29204
- 1711 St. Julian Place
-
Orangeburg, South Carolina, United States, 29118
- Acme Research, Llc
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of systemic lupus erythematosus (SLE) satisfying at least 4 out of the 11 American College of Rheumatology (ACR) criteria (Appendix B)
- Renal biopsy performed consistent with active International Society of Nephrology/Renal Pathology Society (ISN/PRS) class III or IV lupus nephritis
Exclusion Criteria:
- Estimated glomerular filtration rate (GFR) less than or equal to (<=) 30 milliliter per minute (mL/min) per 1.73 square meter (m^2)
- Active central nervous system SLE deemed to be severe or progressive and/or associated with significant cognitive impairment
- Any treatment with MMF, azathioprine, or cyclophosphamide within the last 6 months, or known hypersensitivity to MMF or atacicept.
- Any prior treatment with abatacept, rituximab, belimumab, or other B cell modulating agents.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Atacicept Plus Mycophenolate mofetil Plus Corticosteroids
|
Atacicept will be administered at a dose of 150 milligram (mg) subcutaneously (SC) twice weekly for 4 weeks followed by maintenance dose of 150 mg SC once weekly for 48 weeks.
MMF will be administered orally with a starting dose of 500 mg twice daily for 1 week, will be increased to 1000 mg twice daily for 1 week, then it will be adjusted to 1500 mg or lower twice daily as per investigator's discretion.
High dose CS of 0.8 mg per kilogram per day or maximum of 60 mg per day prednisone or prednisone equivalent, whichever is less will be administered for 4 Weeks and will be tapered to 7.5 to 10 mg/day up to Week 12.
|
|
Placebo Comparator: Placebo Plus Mycophenolate mofetil Plus Corticosteroids
|
MMF will be administered orally with a starting dose of 500 mg twice daily for 1 week, will be increased to 1000 mg twice daily for 1 week, then it will be adjusted to 1500 mg or lower twice daily as per investigator's discretion.
High dose CS of 0.8 mg per kilogram per day or maximum of 60 mg per day prednisone or prednisone equivalent, whichever is less will be administered for 4 Weeks and will be tapered to 7.5 to 10 mg/day up to Week 12.
Placebo will be administered at a dose of 150 mg SC twice weekly for 4 weeks followed by 150 mg SC once weekly for 48 weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Confirmed Complete Renal Response (CRR), Partial Response, and Non-response
Time Frame: At Week 52
|
Complete renal response (CRR): from baseline, a return to within 10% of normal for renal function (assessed by calculated glomerular filtration rate [GFR]), improvement in proteinuria (urine protein/creatinine ratio <0.5) & resolution of hematuria.
Partial response (PR): from baseline, a <= 10% worsening in renal function ( by calculated GFR); 50% improvement in proteinuria (assessed by urine protein/creatinine ratio) & resolution of hematuria, Non-response (NR): Neither criteria for CR or PR was met.
Subjects were also deemed NR if they had treatment failure, regardless of CR or PR status.
Subjects cannot be treatment failures.
A response of CRR was confirmed if the Week 52 value is CRRand if the Week 48 value is CRR and at least 4 weeks apart from Week 52 /if the Week 48 value was missing/ less than 4 weeks from Week 52, then the Week 56 response must be CRR - if the Week 52 value was missing, then Week 48 and Week 56 must be CRR.
|
At Week 52
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of Participants With Normalization of Renal Function
Time Frame: At Week 52
|
At Week 52
|
|
Number of Participants With New Lupus Flares
Time Frame: At Week 52
|
At Week 52
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Medical Responsible, EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Kidney Diseases
- Urologic Diseases
- Connective Tissue Diseases
- Glomerulonephritis
- Lupus Erythematosus, Systemic
- Nephritis
- Lupus Nephritis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antitubercular Agents
- Antibiotics, Antitubercular
- Mycophenolic Acid
Other Study ID Numbers
Other Study ID Numbers
- 28113
- 493G01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.